

VIENNA SEPTEMBER 9 - 13, 2023 eanm23.eanm.org



Learn & Improve Professional Skills (LIPS) Track – Session 1
Oncology & Theranostics Committee
Sunday, September 10, 08:00 – 09.30

Session Title
Novelties in Radionuclide Therapy

Chairpersons
Liliana Violante (Porto, Portugal)

Programme

08:00 - 08:30	Lena Unterrainer (Munich, Germany / Los Angeles, USA): Emerging radiopharmaceuticals in radionuclide therapy
08:30 - 09:00	Arthur Braat (Utrecht, The Netherlands): Intra-arterial Peptide Receptor Radionuclide Therapy
09:00 - 09:30	Zarni Win (London, UK): Pancreatic cancer treatment with P-32

Educational Objectives

- 1. Update of knowledge on radionuclide therapy
- 2. To become aware of new treatment possibilities
- 3. Updating knowledge to improve outcomes

Summary

Radionuclide therapy has increasingly assumed an important role in Oncology. In this session we take radiometabolic therapy future in consideration by giving a particular emphasis on emerging radiopharmaceuticals, on the new approach to PRRT and P-32 application on pancreatic cancer treatment. This session intends to amplify knowledge in order to improve outcomes.

Key Words

Radionuclide therapy, emerging tracers, PRRT, Pancreatic cancer, trials